FDA Alert
10/14/2025
Rebecca Mashaw
The new indication allows for upadacitinib therapy among patients who have received any approved systemic therapy for IBD “in the event TNF blockers are clinically inadvisable."
The new indication allows for upadacitinib therapy among patients who have received any approved systemic therapy for IBD “in the event TNF blockers are clinically inadvisable."
The new indication allows for...
10/14/2025
Advances in Inflammatory Bowel Disease Network